| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
mAChR5 (muscarinic acetylcholine receptor subtype 5, M5).
|
|---|---|
| ln Vitro |
VU 0238429 is a mAChR5 (M5) positive allosteric modulator that has no M2 or M4 enhancer activity, an EC50 of 1.16 μM, and more than 30 times selectivity over M1 and M3.
VU0238429 is a selective positive allosteric modulator of M5 mAChR with an EC50 of 1.16 μM. It shows >30-fold selectivity for M5 over M1 and M3 receptors, with no activity at M2 and M4 receptors. |
| ln Vivo |
No detailed in vivo activity data is available for this compound. As a first-in-class M5 PAM, it is expected to have effects on cerebral blood flow and CNS function, but specific in vivo studies have not been reported.
|
| Enzyme Assay |
The compound's modulation of M5 receptor is assessed in cell-free membrane preparations using radioligand binding assays to confirm binding to the M5 receptor and determine the nature of allosteric modulation.
|
| Cell Assay |
VU0238429 is evaluated in cell-based functional assays using cells expressing recombinant M5, M1, and M3 receptors. Calcium mobilization or other second messenger assays measure the compound's ability to potentiate acetylcholine-induced responses, with EC50 values of 1.16 µM for M5 and >30 µM for M1 and M3.
|
| Animal Protocol |
No detailed in vivo animal experimental protocol is available for this compound. For M5 PAMs, typical in vivo studies involve rodent models to assess effects on cerebral blood flow and cognitive function.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is available for VU0238429. With a molecular weight of 351.28, specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicological data is available for this compound. As a research-grade chemical probe, standard preclinical toxicity assessments have not been published.
|
| References | |
| Additional Infomation |
VU0238429 has a molecular formula of C17H12F3NO4 and a molecular weight of 351.28. It is the first-in-class M5 positive allosteric modulator, providing the essential reference standard for studying M5 receptor function. M5 is thought to regulate cerebral blood flow. The compound has not advanced to clinical trials and is not FDA-approved.
|
| Molecular Formula |
C17H12F3NO4
|
|---|---|
| Molecular Weight |
351.276695251465
|
| Exact Mass |
351.072
|
| CAS # |
1160247-92-6
|
| PubChem CID |
42633508
|
| Appearance |
Light yellow to orange solid powder
|
| LogP |
3.388
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
517
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CKLGZXFOLMHCMC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H12F3NO4/c1-24-11-4-2-10(3-5-11)9-21-14-7-6-12(25-17(18,19)20)8-13(14)15(22)16(21)23/h2-8H,9H2,1H3
|
| Chemical Name |
1-[(4-methoxyphenyl)methyl]-5-(trifluoromethoxy)indole-2,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 150 mg/mL (~427.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8467 mL | 14.2337 mL | 28.4673 mL | |
| 5 mM | 0.5693 mL | 2.8467 mL | 5.6935 mL | |
| 10 mM | 0.2847 mL | 1.4234 mL | 2.8467 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
